Fulcrum Therapeutics (FULC) Earnings Date & Reports

A.I. Advisor

published Earnings

FULC is expected to report earnings to fall 148.28% to -41 cents per share on November 13

Fulcrum Therapeutics FULC Stock Earnings Reports

Q3'24

Est.

$-0.42

Q2'24

Beat

by $1.28

Q1'24

Beat

by $0.01

Q4'23

Beat

by $0.03

Q3'23

Beat

by $0.05

The last earnings report on July 31 showed earnings per share of 87 cents, beating the estimate of -40 cents. With 1.90M shares outstanding, the current market capitalization sits at 235.25M.

View a ticker or compare two or three

Compare

FULC

Setup

Buy or SellView

Daily Signalchanged days ago

Gain/Loss if shorted

View Trends For FULC
(Try 14 days for $1 only)

Ad is loading...

A.I.Advisor

published price charts

View to see Real Time Patterns for FULC (Try 14 days for $1 only)

A.I. Advisor

published General Information

General Information

a clinical-stage biopharmaceutical company, which develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies.

Industry Biotechnology

Profile

Fundamentals

Details

Industry

N/A

Address

26 Landsdowne Street

Phone

+1 617 651-8851

Employees

Web

https://www.fulcrumtx.com